SecBot SecBot
Biotech Drug Report Generated Aug 27, 2026

rinvatercept

KROS·Keros Therapeutics, Inc.
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 2
Time to market
Unknown, the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
Why 5/10
The next hard catalyst is initial data from the Phase 2 Duchenne muscular dystrophy (DMD) trial, expected in H1 2027 (~4-10 months away). This is a Phase 2 readout, not a registration-quality binary, and rinvatercept is one of two key pipeline assets (alongside elritercept partnered with Takeda), so the drug is not the sole company value driver. ImpactScore of 5 reflects a mid-stage asset with a dated catalyst within ~12 months at a ~$200M market-cap company.
Actionable Insight NEUTRAL

Watch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.

Price Chart

Loading chart...

Executive Summary

Rinvatercept (KER-065) is a clinical-stage TGF-beta ligand trap from Keros Therapeutics (KROS, Nasdaq) designed to promote muscle and bone growth. It has completed Phase 1 testing in healthy volunteers with favorable safety and biomarker data, and a Phase 2 trial in Duchenne muscular dystrophy (DMD) was initiated in Q2 2026 with initial data expected in H1 2027. Regulatory engagement for an ALS trial is planned for H2 2026. Keros has a strong cash position ($257.6M, runway into H1 2028) and a $1.3B+ Takeda partnership for its other asset elritercept. The stock trades near its 52-week low (~$11.23) with a mean analyst price target of ~$19.83, but rinvatercept remains an early-stage, binary-risk program with no near-term pivotal readouts.

How It Works

Rinvatercept is a protein-based drug (a ligand trap) designed to block certain signaling molecules in the TGF-beta family that normally limit muscle growth and bone formation. By blocking these signals, rinvatercept aims to promote muscle mass increase and bone density improvement, potentially beneficial in muscle-wasting diseases like Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).

Trial Status

Phase 1 completed in healthy volunteers (data presented March 2026 at MDA Clinical & Scientific Conference). Phase 2 DMD trial initiated in Q2 2026; initial data expected H1 2027. Regulatory engagement for an ALS Phase 2 trial planned for H2 2026.

The Two-Sided Case

▲ Bull Case5
Phase 1 data in healthy volunteers showed target engagement, favorable changes in muscle and bone mass, and a good safety profile, supporting advancement into two Phase 2 trials (DMD and ALS).
Keros has a strong balance sheet with $257.6M in cash providing runway into H1 2028, plus a $1.3B+ global licensing deal with Takeda for its other asset elritercept, which provides validation and potential milestone income.
Analyst consensus is bullish: 9 Buy/Strong Buy vs 0 Sell, with a mean price target of ~$19.83, roughly 69% above the current ~$11.23 price.
Director Jean Jacques Bienaimé has made three consecutive monthly open-market purchases of KROS stock ($10K each in June, July, and August 2026), signaling insider confidence near the stock's 52-week lows.
Multiple institutional investors doubled or added to their KROS positions in Q2 2026, including Mackenzie Financial (+312%), BNP Paribas (+622%), Barclays (+115%), and Jane Street (+159%).
▼ Bear Case5
Rinvatercept is still in early-stage development, Phase 1 only completed in healthy volunteers, with no efficacy data in patients yet. Phase 2 DMD data won't read out until H1 2027, leaving a long period with no near-term binary catalysts.
DMD and ALS are both notoriously difficult indications with high clinical trial failure rates. Multiple prior muscle-building approaches have failed in these diseases.
The stock trades 18.8% below its 200-day SMA ($13.84) and has a 52-week range of $9.69-$22.55, reflecting significant volatility and the binary-risk nature of clinical-stage biotech.
Insider sales in August 2026 by the CSO, CLO, and a director (though some were tax-related sell-to-cover) add a cautionary signal, and several institutional holders trimmed or exited positions in Q2 2026.
The company has no approved products and is pre-revenue, it reported a net loss of $28.7M in Q2 2026 alone.

Upcoming Catalysts

  • Phase 2 DMD trial initial data, expected H1 2027
  • ALS regulatory engagement / Phase 2 trial initiation, planned H2 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Keros Therapeutics, Inc. PRESS-RELEASE KROS ·Originating report

Sources · 5

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 sec.gov5 sec.gov